Totally agree malmanu, considering ovarian & AML trials have been given the green light to proceed with slight change in protocol, one would think similar logic will apply with the phase 2 breast trial. With all that is going on in current ptx200 trials plus kicking off ptx100 in heamotology niche, I'm anticipating an SP re-rate to Edison valuation of 0.29 + is very likely in 2018! See you at the AGM...![]()
- Forums
- ASX - By Stock
- Ann: AGM Presentation
Totally agree malmanu, considering ovarian & AML trials have...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PTX (ASX) to my watchlist
|
|||||
Last
4.2¢ |
Change
-0.001(2.33%) |
Mkt cap ! $33.82M |
Open | High | Low | Value | Volume |
4.4¢ | 4.4¢ | 4.2¢ | $8.214K | 193.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 32561 | 4.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.3¢ | 5169 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 32561 | 0.042 |
1 | 490222 | 0.041 |
9 | 797493 | 0.040 |
6 | 539000 | 0.039 |
3 | 375000 | 0.038 |
Price($) | Vol. | No. |
---|---|---|
0.043 | 5169 | 1 |
0.044 | 225514 | 2 |
0.045 | 845136 | 7 |
0.047 | 525000 | 2 |
0.048 | 308027 | 2 |
Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
Featured News
PTX (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online